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An ethical dilemma
Availability of antiretroviral therapy after clinical trials
with HIV infected patients are ended
Peter E Cleaton›Jones
Professor Cleaton›Jones describes the dilemma faced by South African ethics committees asked to approve clinical trials of
treatments for HIV infection. We asked a member of a patient advocacy group, clinical trial coordinators, an ethicist, and a
representative of a drug company to give their views
Guidelines on good clinical practice for drug trials
clearly state that ethics committees must ensure that
the safety, integrity, and human rights of the subjects
participating in a particular trial are protected.1 Funda›
mental concepts are informed consent and risk or
benefit to participants in a trial. For many clinical trials,
ethical clearance is straightforward but those involving
people infected with HIV generally are not.
Here, we are dealing with a condition that is
presently incurable with variable progression, drug
treatment is expensive, and emotions run high. These
matters are common to all countries, but those of us
living in Africa have an added burden—Third World
conditions and an estimated 13 million people infected
with HIV, usually from heterosexual sex.2 In South
Africa the most recent published results for the fifth
unlinked anonymous national HIV survey show that
HIV infection in women attending antenatal clinics has
risen from a national average of 1.35% in 1991 to
7.57% in 1994.3 In some parts of the country the rate is
as high as 14.35% and is increasing.3 Because of a
shortage of resources, antiretroviral drugs for treating
HIV are not provided by South African public health
services: these are available only in the private sector at
great expense.
Given this high prevalence of HIV it is understand›
able that multinational drug companies are attracted to
carrying out trials in our country, with its combination
of a large infected population and proved medical
expertise. Ethics committees are currently receiving
trial protocols for combinations of drugs from such
companies. All protocols provide for the free supply of
trial drugs for a specified period, usually two to three
years, for patients satisfying the inclusion criteria. The
trials are well designed and comprehensive, but there is
no guarantee that the drug treatment will be continued
beyond the end of the trial. Therein lies the problem.
South African ethics committees use guidelines on
ethics for medical research provided by the South Afri›
can Medical Research Council.4 Comprehensive as
these are, they do not solve the following dilemma.
What is the responsibility of a trial sponsor to a trial
subject who responds to treatment that will not be
available after the end of the trial? With most diseases
this is not a problem since alternative treatments are
available. However, when no other treatment is
available to trialists what should be done? If a patient
infected with HIV responds to the test drugs, may one
ethically withhold the drugs at the end of the trial,
thereby depriving the person of benefit? My commit›
tee’s opinion up to the present has been that it is not
ethical to do so and that such trial subjects must
continue to receive the antiretroviral treatment after
the trial ends until they cease to benefit or are enrolled
into another trial. Naturally, most companies have not
received this opinion with joy. Their argument is that
informed consent, which clearly states the length of a
trial, takes care of the problem. In theory this is correct,
but South Africa has large numbers of people
insufficiently educated to understand the implications
of what they are consenting to.
In early trials, when monotherapy was the rule,
many companies complied with our requirement, but
combination therapy has altered company policy.
Companies often must purchase another manufactur›
er’s drug to use in conjunction with their own. As a
compromise, companies are generally prepared to
provide their trial drug until it is no longer under
development or is commercially available or they will
provide zidovudine alone. Since combination therapy
is the current optimal treatment,5 6 can ethics commit›
tees allow patients to revert back to a less effective
treatment? Furthermore, even if a drug becomes com›
mercially available, is it ethical to halt treatment know›
ing that neither the health service nor trial subject can
afford it?
Investigators fall into two clear camps. Some will
not undertake trials unless there is an arrangement for
their patients to receive drugs long term or to be
enrolled in subsequent trials. Others know that their
patients would normally receive no treatment at all, so
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two to three years of treatment is of some benefit at
least and may buy time for future breakthroughs.
A further complication is the variation in policy of
ethics committees. Our committee, established in 1966,
is the oldest and most experienced in South Africa and
is known to be conservative. Protocols not accepted by
us, we know, have been readily approved in the private
sector or at other institutions. To be fair to all
concerned we have sought personal opinions from
research coordinators in HIV trial groups in Canada
and Australia. In Canada continuation of drug
treatment beyond the trial is expected, but this is
simpler because a drug company can continue to sup›
ply its own drug to be added to the antiretroviral treat›
ment available from the public health services. In
Australia it is accepted that drug companies are
unlikely to provide long term treatment, and
colleagues there believe that monotherapy, with at least
a double nucleoside, after completion of a trial is
acceptable when no other treatment is available.
Realistically, the level of illness required for
inclusion into trials is such that many subjects may not
survive past the trial period. Surely, agreement can be
made on a response to the trial drugs so that only
those responding may continue treatment; those not
responding may be taken out of the trial to free
resources for the responders beyond the trial.
This has been debated at length in our committee
with investigators, trial sponsors, and potential subjects.
The most strident voices of all are those of patients
infected with HIV, who feel that the decision to partici›
pate in a trial is theirs alone, not that of an ethics
committee acting in a paternalistic manner. But ethics
committees have to ensure that patients are not
exploited and that benefit outweighs risk.
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Strident, but essential: the voices of people with AIDS
Peter Busse
In the developed world the voices of advocacy groups
for people infected with HIV have long been strident.
This stridency arose from the behaviour of drug com›
panies, which, together with physicians, were control›
ling access to, and knowledge about, antiretroviral
treatments. Many such groups have a good under›
standing of the required protocols for drug trails and
the available treatments which may prolong lives.
In South Africa the community of people infected
with HIV has yet to raise its strident voice. Its stand is
largely tentative, unarticulated, and mostly ignored. As
a member of NAPWA—the National Association of
People Living With HIV/AIDS—I am part of the grow›
ing community of HIV infected people working to
change this. I attended a meeting of the ethics
committee chaired by Professor Cleaton›Jones at
which a proposed trial protocol was being evaluated. It
was the first time that a member of an advocacy group
had been present. It is, as Cleaton›Jones said in his arti›
cle, our “safety, integrity, and human rights” which are
being decided on, and we must have a voice and be
heard in the debates about which trials will be
supported and undertaken and which will not.
Yet, I found it difficult—because of the diversity of
views and of our ignorance about the debate about
treatment—to confidently articulate the views of my
community on trials of drugs for treating HIV. There is
a tension between investigators and clients with regard
to these trials. To researchers the trials are often seen as
experiments and we are research subjects, whereas to
people like myself the trials are something far more
important: they are seen as treatment rather than
research—and are often the only way in which we in
South Africa have any access to treatment—as well as
being a source of hope that the new drug combination
will prove to be the “magic bullet.” This tension is par›
ticularly acute because the quality of medical care is
highly variable and there is little recognition from the
government or the drug companies of the need to
make effective treatments available at a price that most
people could afford. The final tension is, as
Cleaton›Jones points out, what happens to the
research subjects once the trial is over.
Although there is a strong feeling that it is unethi›
cal to allow people to enter trials when the treatment
will cease after a specified time, many people feel that
access to limited and potentially beneficial treatment is
better than no treatment at all. There is always the
hope that a way will be found for beneficial treatments
to continue. Both these views are debated in the com›
munity of HIV infected people. This is essential so that
when members of our community are asked to give
“informed consent” they have been well prepared,
given Cleaton Jones’s recognition of the inability of
many researchers to explain the protocols clearly and
effectively to those “insufficiently educated to under›
stand the implications of what they are consenting to.”
These tensions need to be resolved. Our voice must
be heard, not in a patronising and glib way, but in a
manner which indicates a real commitment to seeing
our concerns as genuine worries rather than irritating
stridency. Of course, the widely divergent community of
HIV infected people at present allows for investigators
to exploit our differences and lack of detailed knowledge
to engage some sectors but not others. Cleaton›Jones’s
article highlights the need for NAPWA to develop a
Education and debate
NAPWA South
Africa, PO Box
27262, Po Rhine
Road, 8050,
Western Cape,
South Africa
Peter Busse,
executive committee
member, NAPWA
888 BMJ VOLUME 314 22 MARCH 1997
